PRODUCT INFORMATION

BMS 986120
Item No. 23497

CAS Registry No.: 1478712-37-6
Formal Name: 2-methoxy-6-[6-methoxy-4-[(5-methyl-2-(4-morpholinyl)-4-thiazolyl) methoxy]-2-benzofuranyl]-imidazo[2,1-b]-1,3,4-thiadiazole
MF: C_{23}H_{23}N_{5}O_{5}S_{2}
FW: 513.6
Purity: ≥98%
UV/Vis.: \lambda_{\text{max}}: 305 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BMS 986120 is supplied as a crystalline solid. A stock solution may be made by dissolving the BMS 986120 in the solvent of choice. BMS 986120 is soluble in the organic solvent DMSO, which should be purged with an inert gas.

Description

BMS 986120 is an orally bioavailable, selective, and reversible antagonist of proteinase-activated receptor 4 (PAR4; IC_{50} = 0.56 nM) to inhibit calcium mobilization induced by PAR4 agonist peptide (PAR4-AP) in HEK293 cells.\(^1\) It is selective for PAR4 over PAR1, PAR2, and a panel of purified proteases, including thrombin. It inhibits platelet aggregation in vitro in human platelet-rich plasma (IC_{50} = 7.3 nM). BMS 986120 (0.2-1 mg/kg) decreases platelet aggregation induced by PAR4-AP ex vivo in a dose-dependent manner, but does not increase clotting times. In vivo, BMS 986120 (1 mg/kg) prevents vascular occlusion and reduces thrombus formation by 82% in cynomolgus monkeys.

Reference